Spring til hovednavigation
Spring til søgning
Spring til hovedindhold
Region Hovedstadens forskningsportal Forside
Hjælp og OSS
Dansk
English
Forside
Hospitaler/afdelinger
Forskere
Publikationer
Aktiviteter
Priser
Søg efter ekspertise, navn eller tilknytning
The Natural History of IBD: Lessons Learned
Petra Weimers,
Pia Munkholm
Kirurgisk Afd.
Oversigt
Fingeraftryk
Fingeraftryk
Dyk ned i forskningsemnerne om 'The Natural History of IBD: Lessons Learned'. Sammen danner de et unikt fingeraftryk.
Sorter
Vægt
Alfabetisk
Keyphrases
Inflammatory Bowel Disease
100%
Natural History
100%
Lessons Learned
100%
Disease Course
40%
Crohn's Colitis
40%
Positive Impact
20%
Biological Treatment
20%
Surgical Treatment
20%
Epidemiological Data
20%
Relapsed Disease
20%
High Incidence
20%
Treatment Options
20%
Unknown Etiology
20%
Gastrointestinal Tract
20%
Biological Agents
20%
Northern Europe
20%
Disease Monitoring
20%
Immunomodulator
20%
Ulcerative Colitis Patient
20%
Drug Monitoring
20%
Immunosuppressive Drugs
20%
E-health
20%
Natural Disease Course
20%
New Biologics
20%
Northern America
20%
Medical Compliance
20%
Immunosuppressive Diseases
20%
Medicine and Dentistry
Inflammatory Bowel Disease
100%
Disease Course
60%
Crohn's Disease
40%
Ulcerative Colitis
40%
Population
20%
Disease
20%
Malignant Neoplasm
20%
Surgery
20%
Cohort Effect
20%
Prevalence
20%
Recurrent Disease
20%
Immunomodulating Agent
20%
Gastrointestinal Tract
20%
Immunosuppressive Drug
20%
Biological Product
20%
e-Health
20%
Pharmacology, Toxicology and Pharmaceutical Science
Inflammatory Bowel Disease
100%
Disease Course
60%
Ulcerative Colitis
40%
Crohn's Disease
40%
Malignant Neoplasm
20%
Disease
20%
Prevalence
20%
Recurrent Disease
20%
Immunosuppressive Agent
20%
Biological Product
20%
Immunomodulating Agent
20%
Immunology and Microbiology
Inflammatory Bowel Disease
100%
Crohn's Disease
40%
Ulcerative Colitis
40%
Population
20%
Prevalence
20%
Biological Product
20%
Gastrointestinal Tract
20%
Immunomodulating Drugs
20%
Immunosuppressive Drug
20%
Neuroscience
Inflammatory Bowel Disease
100%
Immunosuppressive Drug
20%
Immunomodulating Drugs
20%